IM Cannabis vs Intercure
IMCC and INCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMCC and INCR compare
Intercure grew revenue faster over the last twelve months (13.1% versus 1.3% for IM Cannabis).
Intercure keeps more of each dollar of sales as profit, with a net margin of −13.2% compared with −20.7% at IM Cannabis.
IM Cannabis scores higher on the StockData Score (4 against 3 for Intercure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMCC | INCR |
|---|---|---|
| Size and price | ||
| Share price | $0.495 | $3.79 |
| Change, 1 year | −98.7% | −44.3% |
| Change, 5 years | −100.0% | −90.4% |
| Beta (5Y) | 1.82 | – |
| Employees | 95 | – |
| StockData Score | ||
| Total score | 4 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 | 2 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 1.3% | 13.1% (better) |
| Revenue growth, 5Y average | 28.1% | 33.0% (better) |
| Profitability | ||
| Gross margin | 17.7% (better) | 12.3% |
| Operating margin | −21.2% | −10.1% (better) |
| Net margin | −20.7% | −13.2% (better) |
| FCF margin | 8.6% (better) | 4.9% |
| Return on equity | – | −9.0% |
| Return on invested capital | −82.3% | −4.0% (better) |
| Financial health | ||
| Debt / equity | – | 0.49 |
| Interest coverage | −3.3× | – |
| Current ratio | 0.56 | – |
| Piotroski F-score | 4 | 5 (better) |
| Ownership | ||
| Held by institutions | – | 0.22% |
| Held by insiders | 0.00% | 30.8% |
Go deeper
- IMCC stock overview
- IMCC income statement
- IMCC valuation and score
- INCR stock overview
- INCR income statement
- INCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.